Analysis of Risk Factors Associated with Reduced Trough Concentrations of Vancomycin in Relation to Renal Function in a Tertiary Hospital in Japan

References

• Song JH, Hsueh PR, Chung DR, et al. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother. 2011;66:1061–9.9.21393157
   PubMed Web of Science ®Google Scholar
• Yanagihara K, Matsumoto T, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese society of chemotherapy, the Japanese association for infectious diseases, and the Japanese society for clinical microbiology in 2014: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2019;25:657–668.31196772
   PubMed Web of Science ®Google Scholar
• Isobe M, Uejima E, Seki M, et al. J methicillin-resistant Staphylococcus aureus bacteremia at a university hospital in Japan. Infect Chemother. 2012;18:841–848. doi:10.1007/s10156-012-0423-6
   Web of Science ®Google Scholar
• Seki M, Yabuno K, Miyawaki K, Miwa Y, Tomono K. Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features. Clin Pharmacol. 2012;4:71–75.23236257
   PubMedGoogle Scholar
• Matsumoto K, Takesue Y, Ohmagari N, et al. Revised practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. Jpn J Chemother. 2016;1:1–120.
   Google Scholar
• Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. J Infect Chemother. 2013;19:365–380. doi:10.1007/s10156-013-0599-423673472
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77:835–864.32191793
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942. doi:10.2165/00003088-200443130-0000515509186
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–292. doi:10.1093/cid/cir03421217178
   PubMed Web of Science ®Google Scholar
• Issaranggoon NA, Ayuthaya S, Katip W, Oberdorfer P, Lucksiri A. Correlation of the vancomycin 24-h area under the concentration-time curve (AUC 24) and trough serum concentration in children with severe infection: a clinical pharmacokinetic study. Int J Infect Dis. 2020;92:151–159. doi:10.1016/j.ijid.2019.12.03631935538
   PubMed Web of Science ®Google Scholar
• Kamioka Y, Suzuki H, Seki M, et al. After Deriving the Initial Dose Setting of Vancomycin with a conventional computer software and a nomogram based on the revised Japanese 2016 therapeutic drug monitoring guidelines for antimicrobial agents. Pharmacol Pharm. 2018;9:88488. doi:10.4236/pp.2018.911037
   Google Scholar
• Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Jpn J Nephrol. 2012;54:1031–1191.
   Google Scholar
• Katip W, Jaruratanasirikul S, Pattharachayakul S, Wongpoowarak W, Jitsurong A, Lucksiri A. The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock. Infect Drug Resist. 2016;22:253–260. doi:10.2147/IDR.S121513
   Web of Science ®Google Scholar
• Cook AM, Hatton-Kolpek J. Augmented renal clearance. Pharmacotherapy. 2019;39:346–354. doi:10.1002/phar.223130723936
   PubMed Web of Science ®Google Scholar
• Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013;39:1247–1252. doi:10.1007/s00134-013-2909-923604132
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–810. doi:10.1001/jama.2016.028726903338
   PubMed Web of Science ®Google Scholar
• Masuda N, Maiguma T, Komoto A, Haruki Y, Sugiyama T, Teshima D. Validation of vancomycin nomogram using eGFR to calculate initial dosages as stated in the TDM guideline for antibiotics 2016: study in patients with mild to moderate renal dysfunction. Jpn J Ther Drug Monit. 2017;34:132–136.
   Google Scholar
• Suzuki A, Tawada H, Namiki M, Ikeda H, Kogo M, Sasaki T. Impact of trough concentration for vancomycin therapy with initial dosage. Jpn J Environ Infect. 2017;32:250–257. doi:10.4058/jsei.32.250
   Google Scholar
• Tsutsuura M, Moriyama H, Kojima N, et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis. 2021;21:153. doi:10.1186/s12879-021-05858-633549035
   PubMed Web of Science ®Google Scholar
• Covvey JR, Erickson O, Fiumara D, et al. Comparison of vancomycin area-under-the-curve dosing versus trough target-based dosing in obese and nonobese patients with methicillin-resistant Staphylococcus aureus Bacteremia. Ann Pharmacother. 2020;54:644–651. doi:10.1177/106002801989710031888350
   PubMed Web of Science ®Google Scholar